EGFR and non-small cell lung carcinoma: In the pivotal phase III MARIPOSA trial, the combination of lazertinib and amivantamab improved overall survival (OS) for previously untreated epidermal growth factor receptor (EGFR, exon 19 deletion or exon 21 L858R point mutation)-mutated metastatic non-small cell lung cancer (NSCLC) when compared to osimertinib monotherapy.